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Complexity generation by chemical synthesis:
a five-step synthesis of (−)-chaetominine from
L-tryptophan and its biosynthetic implications†‡
Chu-Pei Xu,a Shi-Peng Luo,a Ai-E Wanga and Pei-Qiang Huang*a,b
We demonstrated, for the first time, that on the basis of chemistry
principles, the hexacyclic peptidyl alkaloid (−)-chaetominine (1)
can be synthesized in a straightforward manner from L-Trp. The
approach features the efficient generation of molecular complexity
via a tandem C3/C14 syn-selective epoxidation (dr = 3 : 2)–annula-
tive ring-opening reaction and a regioselective epimerization at
C14. The successful production of (−)-chaetominine (1) from L-Trp
could be helpful for revealing how the configuration of L-trypto-
phan becomes inverted in the biosynthetic pathway of (−)-chaeto-
minine (1).
An ideal synthesis is the ultimate goal in the field of the total
synthesis of complex natural products.1 Biomimetic synthesis
is one of the most efficient strategies for this aim.2 However,
most biogenetic pathways are unknown or unconfirmed by
incorporation experiments.3 Even the biosynthesis of simple
tropane alkaloids remains an unsolved century-old problem.4
A biosynthetic perspective has turned out to be helpful in
designing highly efficient synthetic approaches and tremen-
dous progress has been made recently.2,5,6 In this context, the
total synthesis of natural products plays an important role in
postulating and confirming biogenetic pathways.2,5–7
(−)-Chaetominine (1) (Fig. 1) is a hexacyclic alkaloid iso-
lated first from the solid-substrate culture of Chaetomium sp.
IFB-E015, an endophytic fungus on apparently healthy Adeno-
phora axilliflora leaves,8a,9 and later from the metabolites of
Aspergillus sp. HT-2 collected from Guizhou province, China.8b
The characteristic tetracyclic core structure of (−)-chaetomi-
nine (1) (but with a different stereochemical pattern) is also
found in kapakahines (e.g. 2 and 3 in Fig. 1), a group of seven
cyclic peptides isolated from the marine sponge Cribrochalina
olemda.10,11 Like many other peptidyl alkaloids isolated from
the fungal genus Aspergillus,12a (−)-chaetominine also pos-
sesses a quinazolinone ring system.12 It is interesting that a
non-proteinogenic D-Trp residue is incorporated in (−)-chaeto-
minine. The synthesis9,11,14 and biosynthesis13 of these com-
pounds have therefore attracted much attention. Thanks to the
seminal work of Walsh, Tang and co-workers, efficient biosyn-
thetic pathways for complexity generation have been revealed
for several peptidyl alkaloids.13 Tan8a and Walsh/Tang13b have
independently suggested two plausible biosynthetic pathways
to (−)-chaetominine (1) (pathways A and B in Scheme 1), in
which the tetracyclic core is constructed via an intramolecular
oxidative cyclization of nine-membered bislactam A or C.
We envisioned another scenario that involves compound 4
as the direct precursor for intramolecular oxidative cyclization
(Scheme 2). On the basis of this consideration, we have devel-
oped a bio-inspired four-step total synthesis of (−)-chaeto-
minine (1) from D-tryptophan (Scheme 2).9c,f The synthesis
is remarkably concise and efficient, except that the diastereo-
selectivity is unsatisfactory in the epoxidation step, which
gives the desired α-epoxide (α-5) as the minor product.
On the other hand, although L-tryptophan has been
suggested to be the starting material in the biosynthesis of
(−)-chaetominine (1),8a,13a,15 all the reported total syntheses of
(−)-chaetominine (1) used D-Trp as a starting material.9 More-
over, in the proposed biosynthetic pathways, how the configur-
ation of L-tryptophan becomes inverted is still obscure. Since
Fig. 1 Structures of (−)-chaetominine (1) and kapakahines B and F.
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there exist three possible ways for a non-proteinogenic
D-amino acid to be incorporated into a natural product,16 figur-
ing out the origin of the D-tryptophan residue in chaetominine
(1) is important for understanding the biogenetic route of
chaetominine (1). Within this context, we embarked on a
project to see if on the basis of chemistry principles, (−)-chae-
tominine (1) could be synthesized in a straightforward manner
starting from L-Trp. The results of this investigation are
reported herein.
In our first generation total synthesis of (−)-chaetominine
(1) from D-Trp (Scheme 2),9c,f C3/C14 syn-selection was
obtained in the epoxidation of tripeptide 4. In addition, con-
comitant epimerization at C14 was observed in the base-
promoted cyclization of compound 7 to compound 8.9f In con-
nection with the spontaneous formation of (−)-chaetominine
(1) from amino ester 6 observed in the epoxidation step, we
assumed that the epimerization at C14 of 7 occurred first to
give 7a, which facilitated a subsequent tandem lactamization
reaction to produce 8 (Scheme 2). Therefore, it is possible
to undertake an unprecedented total synthesis of (−)-chaeto-
minine (1) starting from L-tryptophan by taking advantage of
both the observed C3/C14 syn-diastereoselective epoxidation
and the base-promoted epimerization at C14.
The synthesis commenced with the aroylation of L-trypto-
phan with o-nitrobenzoyl chloride (THF, 1 M NaOH, 0 °C, 2 h),
which produced compound (S)-9 in 91% yield (Scheme 3).
Treatment of compound 9 with i-BuOCOCl–N-methylmorpho-
line (NMM, THF, −30 °C, 60 min) gave the corresponding acti-
vated ester, which reacted in situ with L-alanine methyl ester
hydrochloride salt (THF, NMM, −20 °C, 12 h) to yield the
dipeptide derivative 10 in 93% yield. The quinazolinone ring
system12 was constructed by a minor modification of Shi’s
method.17 10 was thus treated with HC(OMe)3 and low valent
titanium, generated in situ from TiCl4 and Zn powder in THF
at 50 °C, to give the desired quinazolinone 11 in 95% yield. For
the key epoxidation triggered tandem reaction, our previously
established conditions9c,f were modified to improve the yield
of the desired diastereomer. In this study, the treatment of qui-
nazolinone 11 with DMDO18 in acetone at −78 °C followed by
work-up with aqueous Na2SO3 produced the mono-cyclized
product 12 in 48% yield along with 2,3,14-tri-epi-chaetominine
(8) in 32% yield. A similar result was obtained when the reac-
tion was run at −95 °C. Performing the epoxidation under
Shi’s asymmetric epoxidation conditions,19 or with m-CPBA,
Oxone, hydrogen peroxide and Davis’ N-sulfonyloxaziridine,20
led only to the recovery of the starting material.
We next proceeded to investigate the selective epimerization
at C14 of compound 12. Unexpectedly, the treatment of 12
with MeONa in MeOH at −10 °C produced the C14 and C11
bis-epimerized product (−)-11-epi-chaetominine (ent-8) in 82%
yield. The use of other inorganic bases such as K2CO3 or
organic bases such as Et3N, DBU, DBN and TMG did not give
improved results. After extensive trials, it was found that by
heating a toluene solution of 12 in the presence of 0.1 equiv of
Scheme 1 Key steps of the plausible biosynthetic pathways for
(−)-chaetominine (1) proposed by Tan (pathway A) and Walsh/Tang
(pathway B).
Scheme 2 The key cascade reaction in our previous four-step total synthesis of (−)-chaetominine (1) from D-tryptophan and a transformation of
compound 7.
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DMAP for 7 days, (−)-chaetominine (1) was obtained in a
respectable yield of 60%, alongside 19% of the bis-epimerized
product (−)-11-epi-chaetominine (ent-8).
Consistent with the results from the epoxidation of quina-
zolinono-dipeptide 4 (D-Trp-L-Ala-OMe) (Scheme 2),18d,e the
epoxidation of L-Trp-L-Ala-OMe derivative 11 proceeded with a
3 : 2 C3/C14 syn/anti diastereoselectivity to produce compound
12 as the major product (Scheme 3). These results imply that
the Trp residue predominates over the Ala residue in asym-
metric induction. The syn-stereoselectivity can be explained by
the model11b suggested by Danishefsky.21
In addition, the direct formation of chaetominine (1) from
4 (Scheme 2), and 8 from 11 (Scheme 3) implies that an anti-cis
arrangement of the hydroxyl group at C3 and the quinazolino-
nyl group favors lactamization. By contrast, the syn-diastereo-
mers 7 and 12 failed to lactamize because of the steric
hindrance between the hydroxyl group at C3 and the quinazoli-
nonyl group. A base-promoted epimerization at C-14 of 7 and
12 relieves the steric hindrance and results in tandem lactami-
zation to give 8 (Scheme 2) and chaetominine (1) (Scheme 3),
respectively.
The chemical information we gained during these studies
of the synthesis of (−)-chaetominine (1) allowed us to suggest
a plausible biosynthetic pathway for (−)-chaetominine (1)
(Scheme 4). Our hypothesis involves epoxidation-triggered
lactamization which converts tripeptide derivative E to F, and
the selective epimerization at C14 of the intermediate G
that triggers the subsequent lactamization to produce (−)-chae-
tominine (1).
Conclusions
In conclusion, we have shown that L-tryptophan, o-nitroben-
zoyl chloride, L-alanine, and anthranilic acid can be assembled
Scheme 3 The five-step synthesis of (−)-chaetominine (1) from L-tryptophan. Reagents and conditions: (i) o-nitrobenzoyl chloride, 1 M NaOH, THF,
0 °C; (ii) H-L-Ala-OMe·HCl, ClCO2
iBu, NMM, THF, −20 °C; (iii) HC(OMe)3, Zn/TiCl4, THF, 0 °C; (iv) DMDO, THF, −78 °C, 1 h; Na2SO3 (aq.), 0 °C; (v)
DMAP (0.1 equiv.), tol., reflux, 7 days.
Scheme 4 Plausible biosynthetic pathway of (−)-chaetominine (1) from L-Trp.
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in five steps to give (−)-chaetominine (1) with an overall yield
of 23.2%, and (−)-11-epi-chaetominine (ent-8) with an overall
yield of 31.7%. This validation of L-Trp as a starting material
in the chemical synthesis of (−)-chaetominine has some impli-
cations for the biosynthesis of (−)-chaetominine: (1) L-Trp
might be the starter unit; (2) instead of an early inversion
of configuration of D-Trp to L-Trp, an epimerization at C-14
of a tripeptide intermediate may possibly establish the
R-configuration at C-14 of (−)-chaetominine; (3) the acyclic
tripeptide derivative 11 (cf. A and C in Scheme 1) may serve as
a ready precursor of (−)-chaetominine. The total synthesis also
serves as a good example of step economy and redox economy,
as well as the protecting-group-free and complexity-generating
synthesis of structurally complex natural products.
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